Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   42568   clinical trials with a EudraCT protocol, of which   7009   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2007-001625-10
    Sponsor's Protocol Code Number:0881X1-4437(Amendment1,19March2008)
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2009-04-01
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2007-001625-10
    A.3Full title of the trial
    An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity.
    An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity.
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code number0881X1-4437(Amendment1,19March2008)
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorWyeth Pharmaceuticals France
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name ENBREL
    D. of the Marketing Authorisation holderWYETH LEDERLE SpA
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNETANERCEPT
    D.3.9.1CAS number 185243690
    D.3.9.2Current sponsor codeWAY-143050
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Rheumatoid Arthritis
    Artrite Reumatoide
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the impact of ETN + MTX in comparison with usual treatment on radiographic disease progression at 52 weeks in subjects with moderate RA who failed treatment with MTX.
    Valutare l'effetto di ETN 50 mg una volta alla settimana in associazione a MTX in confronto con il trattamento standard sulla progressione radiografica di malattia a 52 settimane in soggetti con RA moderata che non hanno risposto al trattamento con MTX.
    E.2.2Secondary objectives of the trial
    •To compare the effects of ETN + MTX and usual treatment on clinical outcomes •To compare the effects of ETN + MTX and usual treatment on health-related quality of life and dimensions of impact of disease on subjects over 52 weeks. •To evaluate the safety of the treatment regimen over 52 weeks.
    •Confrontare gli effetti di ETN 50 mg una volta alla settimana in associazione a MTX sui risultati clinici.•Confrontare gli effetti di ETN 50 mg volta alla settimana in associazione a MTX sulla qualita' di vita e sulla dimensione dell'impatto della malattia sui soggetti per 52 settimane.•Valutare la sicurezza del regime di trattamento per 52 settimane.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Titolo: Proprieta' psicometriche della sinovite misurata con l'ultrasonografia nell'artrite reumatoide: uno studio ancillare di 'etarnecept versus DMARDs' nell'AR moderata
    Data Versione: 09/01/2008

    E.3Principal inclusion criteria
    ¿18 years of age or older at time of consent. ¿Meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis. ¿Active Rheumatoid Arthritis: evidence of clinical signs of joint inflammation / swelling at screening and randomization. ¿Documented evidence, confirmed by a blinded 3rd party assessor, of at least one erosion observed by X-ray (hands or feet) at randomization based on X-ray taken at the screening visit. Subjects with no confirmed erosion at the randomization visit are to be withdrawn. ¿¿ Plasma C-reactive protein level of at least 8.0 mg/L or Erythrocyte Sedimentation Rate of at least 28 mm/h in sample taken at the screening visit. ¿¿ Currently receiving optimized* treatment with MTX but with active disease as defined by a DAS28 score of >&#61619;3.20 and &#8804;<5.10 at both the screening and randomization visits. The erythrocyte sedimentation rate (ESR) value at the screening visit will be used for the DAS 28 calculation at the randomization visit * Have received MTX orally, intramuscularly or SC for at least 4 months before screening with at least 2 months at the highest tolerated dose (not less than 12.5mg/week). ¿Functional status Class I, II or III as defined by ACR Revised Criteria. ¿Onset of disease after 16 years of age. ¿In the opinion of the investigator, the subject will be able to comply with the requirements of the protocol, including ability to present for all required visits. ¿Capable of understanding and willing to provide signed and dated written, voluntary informed consent before any protocol-specific procedures are performed. ¿Able and willing to self-inject study drug or have a designee who can do so. ¿Able and willing to take oral medication.
    ¿Eta` minima di 18 anni compiuti al momento della firma del consenso. ¿Pazienti che soddisfino gli ACR Revised Criteria for Rheumatoid Arthritis - 1987. ¿Artrite Reumatoide attiva: evidenza di segni clinici di infiammazione/rigonfiamento articolare allo screening e alla randomizzazione. ¿Evidenza documentata, confermata da una terza parte in cieco, di almeno una erosione osservata attraverso i raggi X (mani o piedi) alla visita di randomizzazione, basandosi sulle radiografie effettuate alla visita di screening. I soggetti che non presentino erosioni confermate alla visita di randomizzazione, saranno discontinuati. ¿ Livelli di proteina C-reattiva nel plasma di almeno 8.0 mg/L nel campione prelevato alla visita di screening o velocita` di sedimentazione della emazie di almeno 28 mm/ora.. ¿ Pazienti che stiano ricevendo un trattamento ottimizzato* con MTX ma con una malattia attiva, definita mediante un valore di DAS28 &gt;3.20 e &lt;5.10 sia alla visita di screening che alla visita di randomizzazione. La velocita` di sedimentazione eritrocitaria (ESR) alla visita di screening sara` utilizzata per il calcolo di DAS28 alla visita di randomizzazione. * Abbiano ricevuto MTX orale, intramuscolo o SC per almeno 4 mesi prima dello screening, con almeno 2 mesi alla dose massima tollerata (non meno di 12.5 mg/settimana). ¿Pazienti che abbiano ricevuto MTX ad una dose stabile nei 28 giorni precedenti lo screening. ¿Pazienti che, secondo il parere dello sperimentatore, possano continuare il trattamento con MTX ad una dose di 12.5 mg/settimana o superiore, ma comunque non superiore a 25 mg/settimana. ¿Stato funzionale di Classe I, II o III definito secondo gli ACR Revised Criteria ¿Comparsa della malattia dopo i 16 anni di eta`. ¿A discrezione dello sperimentatore, il soggetto sia in grado di attenersi alle richieste del protocollo, inclusa la capacita` di presentarsi a tutte le visite richieste. ¿Il soggetto sia in grado di capire e di firmare volontariamente un consenso informato prima che qualsiasi procedura dello studio sia avviata. ¿Il soggetto sia in grado di auto iniettarsi ETN o abbia qualcuno che lo possa fare. ¿Il soggetto sia in grado di assumere una terapia orale.
    E.4Principal exclusion criteria
    ¿Previous treatment with ETN, infliximab, adalimumab, other TNF-alfa inhibitors, anakinra or other biological agents. ¿Receipt of any DMARD, other than MTX, within 28 days before screening. ¿Unable to tolerate MTX at a minimum dose of 12.5 mg/week orally, intramuscularly or SC. ¿Known significant (in the opinion of the investigator) concurrent medical disease including: ¿Uncompensated congestive heart failure, or class III or IV heart failure defined by the New York Heart Association classification. ¿History of or current pancytopenia or aplastic anemia. ¿Diagnosis of multiple sclerosis or other central or peripheral nervous system demyelinating diseases. ¿Current malignancy or an individual history of cancer (other than resected basal cell carcinoma of the skin) within five years of the screening visit. ¿Active infection including known human immunodeficiency virus (HIV) infection and tuberculosis (TB) (Note: follow local country guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-TNF therapy). ¿Sepsis, or at risk of sepsis. ¿Subjects with signs of immunodeficiency. ¿Other current autoimmune connective tissue diseases such as diagnosis of systemic lupus erythematosus, scleroderma, or polymyositis. ¿Significant renal disease in the investigator¿s opinion ¿Abnormal hematology or chemistry profiles: ¿white blood cell (WBC) count < o = 3.5 x 109/L ¿ Hemoglobin level < o = 85 g/L or 5.3 mmol/L ¿ Hematocrit < o = 27%. ¿ Platelet count < o = 125 x 109/L ¿ Serum creatinine level > o = 175 umol/L ¿ Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > o = 2 times the laboratory¿s upper limit of normal ¿ Clinically significant abnormal screening laboratory values in the investigator¿s opinion (based on country-specific standard of care) ¿ Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception. ¿ Use of any investigational treatment or device within 3 months (or 5 half lives of the treatment, whichever is longer) of the screening visit. ¿ Concomitant oral corticosteroid >10 mg/day of prednisone or its equivalent at the point of screening (corticosteroid dose must be stable for at least 4 weeks prior to screening). ¿ Intra-articular, intravenous, intramuscular or subcutaneous (SC) corticosteroid injection within 28 days of the screening visit. ¿ Active alcoholism and/or substance abuse within one year of the screening visit. ¿Conditions requiring initiation of new drug therapy concurrent with entry into this study.
    ¿Precedente trattamento con ETN, infliximab, adalimumab, altri inibitori del TNF-alfa, anakinra o altri agenti biologici. ¿Assunzione di qualsiasi DMARD, ad eccezione di MTX, entro 28 giorni dallo screening. ¿Incapace di tollerare MTX alla dose minima di 12.5 mg/settimana orale, intramuscolare o SC. ¿Malattie concomitanti conosciute e significative (a discrezione dello sperimentatore), comprese: ¿Scompenso cardiaco congestizio o scompenso cardiaco di classe III o IV, secondo la classificazione del New York Heart Association ¿Pancitopenia o anemia aplastica pregresse o concomitanti. ¿Diagnosi di sclerosi multipla o altre malattie demielinizzanti del sistema nervoso centrale o periferico. ¿Storia individuale di cancro entro cinque anni dalla visita di screening o altri tumori maligni concomitanti (ad eccezione di carcinoma della pelle a cellule basali precedentemente asportato). ¿Infezioni attive, incluso virus da immunodeficienza (HIV) conosciuto e tubercolosi (TB) (nota: seguire le linee guida locali per lo screening e il trattamento della tubercolosi nella terapia con anti-TNF). ¿Sepsi o rischio di sepsi. ¿Soggetti con segni di immunodeficienza. ¿Altre malattie autoimmuni concomitanti del tessuto connettivo, come il lupus eritematoso sistemico, sclerodermia o polimiosite. ¿Malattia renale significativa secondo l¿opinione dello sperimentatore. ¿Profilo di ematologia o biochimica anormali: ¿Globuli bianchi (WBC) &lt; o = 3.5 x 109/L ¿Emoglobina &lt; o = 85 g/L o 5.3 mmol/L ¿ Ematocrito &lt; o = 27%. ¿ Conta delle piastrine &lt; o = 125 x 109/L ¿ Creatinina Serica &gt; o = 175 umol/L ¿ Aspartato aminotransferasi (AST) o alanina aminotransferasi (ALT) &gt; o = 2 volte il limite superiore di normalita` ¿ Valori anormali di laboratorio alla visita di screening e considerati dallo sperimentatore clinicamente significativi (secondo gli standard di riferimento del paese in questione). ¿ Donne in gravidanza, che stiano allattando o a rischio di gravidanza e che non stiano usando un metodo accettabile di contraccezione. ¿ Uso di qualsiasi trattamento o dispositivo sperimentale entro 3 mesi dalla visita di screening (o entro 5 emivite del farmaco, a seconda di quale sia piu` lunga). ¿ Assunzione concomitante di corticosteroidi orali ad una dose &gt; di 10 mg/giorno di prednisone o suoi equivalenti al momento dello screening (la dose di corticosteroidi deve essere stabile da almeno 4 settimane prima dello screening). ¿ Iniezione di corticosteroidi intra-articolare, endovena, intramuscolo o sottocute (SC) nei 28 giorni precedenti la visita di screening. ¿ Alcolismo attivo e/o assunzione di sostanze di abuso entro un anno dalla visita di screening. ¿ Condizioni che richiedano l¿inizio di una nuova terapia farmacologica concomitante con l¿ingresso in studio.
    E.5 End points
    E.5.1Primary end point(s)
    Change from randomization in modified Total Sharp Score (TSS) at 52 weeks.
    Variazione del TSS nel periodo intercorrente dalla randomizzazione a 52 settimane.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA100
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months30
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months30
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2009-04-01. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 639
    F.4.2.2In the whole clinical trial 700
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2008-09-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2008-11-26
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice